Regulation 4 The National Health Service (Wales) Act 2006I1
United Kingdom
The NHS (Wales) Act is amended as follows.
In section 46 (GMS contracts: prescription of drugs, etc)—
in subsection (3), for “Community marketing authorization or United Kingdom” substitute “ UK ”;
for subsection (4) substitute—
“(4)“UK marketing authorisation” has the meaning given by regulation 8(1) of the Human Medicines Regulations 2012 (S.I. 2012/1916).”.
Omit the following provisions—
section 6A (reimbursement of cost of services provided in another EEA state) M1;
section 6B (prior authorisation for the purposes of section 6A) M2;
section 6BA (reimbursement of cost of services provided in another EEA state where expenditure incurred on or after 25 October 2013) M3;
section 6BB (prior authorisation for the purposes of section 6BA) M4;
section 131(a)(ii) (payment of travelling expenses) M5;
the definition of “Regulation (EC) No. 883/2004” in section 206(1) (interpretation) M6 except in so far as it relates to section 131(a)(iii).
Annotations
Marginal citations
- M1
Section 6A was inserted by S.I. 2010/915 and amended by S.I. 2013/2269.
- M2
Section 6B was inserted by S.I. 2010/915 and amended by S.I. 2013/2269.
- M3
Section 6BA was inserted by S.I. 2013/2269.
- M4
Section 6BB was inserted by S.I. 2013/2269.
- M5
Section 131(a) was substituted by S.I. 2010/915 and amended by S.I. 2013/2269.
- M6
The definition was inserted by S.I. 2010/915.
Commencement
- I1
Reg. 4 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1(1)